FDA clears Roche’s bispecific Eylea contender, but can it compete with the Regeneron blockbuster?
The FDA finally approved Roche-Genentech’s Eylea rival late Friday, although precisely how much the long-acting antibody can cut into Regeneron’s blockbuster sales remains unclear. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
